Abstract
BackgroundIn ACT-RAY, MTX-IR patients (pts) with moderate to severe RA were randomized to either the add-on (TCZ+MTX) or the switch (TCZ+placebo [PBO]) strategy arm. 24- and 52-week data demonstrated clinical...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have